Moving erlotinib from formulary tier 3 to tier 2 resulted in lower copayments and higher treatment persistence among lung cancer patients.
Nicole M. Engel-Nitz, PhD
Advertisement
Articles by Nicole M. Engel-Nitz, PhD
Advertisement
Latest Updated Articles
- Lung Cancer: Copayments and Behavior Following Erlotinib Formulary Tier Change
Published: November 13th 2012 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Interview with Sa'ed al-Olimat, PharmD: How Pharmacists are Shaping the Future of Psychedelic Therapy
2
December 2025 Product Updates
3
A Healthy Gut Could Improve Mental Health
4
Reimagining Pharmacy: A Call to Action for Pharmacy Professionals
5